NF International Equity Unhedged (2513)

Overview

ZyVersa Therapeutics, Inc. is a clinical stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of renal and inflammatory diseases. Founded in 2014 and based in Weston, Florida, ZyVersa focuses on advancing its proprietary drug development platforms towards clinical trials, aiming to address the unmet medical needs in various renal indications and inflammatory conditions. With a commitment to innovation, ZyVersa seeks to improve patient outcomes through scientifically backed research and the development of effective treatments.

Products and Services

• Cholesterol Efflux Mediator VAR 200

An injectable drug currently in Phase 2a clinical trial, aimed at treating renal indications such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases. VAR 200 functions by potentially altering cholesterol metabolism, thereby addressing the underlying mechanisms of these kidney conditions.

• Inflammasome ASC Inhibitor IC 100

A humanized monoclonal antibody in the preclinical stage, designed for the treatment of a variety of inflammatory diseases. These include but are not limited to acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity. IC 100 targets the inflammasome ASC, a critical component in the inflammatory process, offering a novel approach to treating inflammation-related diseases.